Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25879050 | 0.92 | OPRM1 (0.45) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL25793979 | 0.86 | OPRM1 (0.54) | OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL25523481 | 0.85 | ALDH1A1 (0.49) | ALDH1A1DDB1CRBN | |
| SCHEMBL16488071 | 0.84 | OPRM1 (0.51) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL31297843 | 0.83 | DDB1 (0.51) | ALDH1A1DDB1CRBN | |
| SCHEMBL24568094 | 0.83 | OPRM1 (0.50) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL13411094 | 0.82 | OPRM1 (0.75) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL22014538 | 0.82 | OPRM1 (0.52) | OPRM1SLC22A1SLC6A4ADRA1AOPRD1 | |
| SCHEMBL24969422 | 0.80 | ALDH1A1 (0.46) | ALDH1A1DDB1CRBN | |
| SCHEMBL6272646 | 0.80 | CYP3A4 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | OPRM1 2659/4885SLC22A1 4427/4885SLC6A4 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.